Fundraising Fox

Indaptus Therapeutics

NASDAQ: INDP

New York, US · Founded 2021 · Delaware corporation

Biotech

Founders & leadership

Indaptus Therapeutics was founded in 2021 by MICHAEL J. NEWMAN.

MJ
MICHAEL J. NEWMANFounder
RW
ROGER WALTZMANExecutive
JA
JEFFREY A. MECKLERExecutive
NS
NIR SASSIExecutive
WA
WALT A LINSCOTTExecutive
HL
HOONMO LEENamed on SEC filing
BO
BRIAN O'CALLAGHANNamed on SEC filing

Board

AM
ANTHONY MADDALUNABoard director
WB
WILLIAM B. HAYESBoard director
RE
ROBERT E. MARTELLBoard director
RJ
ROGER J. POMERANTZBoard director
HK
HILA KARAHBoard director

Reported raises · per SEC filings

Form D private placements

$35M disclosed across 5 rounds · 2021–2025

▶$2.3MraisedJun 2025 · 20 investors · Pharmaceuticals
Rule 506(c)
Officers, directors & promoters on the filing
  • Anthony MaddalunaDirector
  • Hila KarahDirector
  • Robert E. MartellDirector
  • Walt A. LinscottExecutive Officer
  • Roger PomerantzDirector
  • William B. HayesDirector
  • Mark J. GilbertDirector
  • Roger J. WaltzmanExecutive Officer
  • Michael J NewmanExecutive Officer, Director
  • Jeffrey A. MecklerExecutive Officer, Director
  • Nir SassiExecutive Officer
Offering amount
$5M
Amount sold
$2.3M
Sales commissions
$600K
Placement agents
Paulson Investment Company, LLC
First sale
Jun 2025
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$2.2MraisedJan 2025 · 16 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • ROGER J. POMERANTZDirector
  • ANTHONY MADDALUNADirector
  • ROGER WALTZMANExecutive Officer
  • MARK J GILBERTDirector
  • MICHAEL J. NEWMANExecutive Officer, Director
  • JEFFREY A. MECKLERExecutive Officer, Director
  • NIR SASSIExecutive Officer
  • WALT A LINSCOTTExecutive Officer
  • WILLIAM B. HAYESDirector
  • HILA KARAHDirector
  • ROBERT E. MARTELLDirector
Offering amount
$2.2M
Amount sold
$2.2M
Sales commissions
$157.3K
Placement agents
Paulson Investment Company, LLC
First sale
Jan 2025
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$227.1KraisedDec 2024 · 20 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • MARK J GILBERTDirector
  • MICHAEL J. NEWMANExecutive Officer, Director
  • NIR SASSIExecutive Officer
  • WILLIAM B. HAYESDirector
  • ROGER WALTZMANExecutive Officer
  • WALT A LINSCOTTExecutive Officer
  • ANTHONY MADDALUNADirector
  • JEFFREY A. MECKLERExecutive Officer, Director
  • HILA KARAHDirector
  • ROGER J. POMERANTZDirector
  • ROBERT E. MARTELLDirector
Offering amount
$227.1K
Amount sold
$227.1K
Sales commissions
$15.5K
Placement agents
Paulson Investment Company, LLC
First sale
Nov 2024
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$205.5KraisedOct 2024 · 12 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • ANTHONY MADDALUNADirector
  • WILLIAM B. HAYESDirector
  • MICHAEL J. NEWMANExecutive Officer, Director
  • ROBERT E. MARTELLDirector
  • ROGER WALTZMANExecutive Officer
  • JEFFREY A. MECKLERExecutive Officer, Director
  • ROGER J. POMERANTZDirector
  • HILA KARAHDirector
  • NIR SASSIExecutive Officer
  • MARK J GILBERTDirector
  • WALT A LINSCOTTExecutive Officer
Offering amount
$205.5K
Amount sold
$205.5K
Sales commissions
$17.5K
Placement agents
Paulson Investment Company, LLC
First sale
Aug 2024
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$30MraisedAug 2021 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • HOONMO LEEDirector
  • MICHAEL NEWMANExecutive Officer, Director
  • ANTHONY J. MADDALUNADirector
  • ROGER J. POMERANTZDirector
  • HILA W. KARAHDirector
  • JEFFREY A. MECKLERExecutive Officer, Director
  • WILLIAM B. HAYESDirector
  • BRIAN O'CALLAGHANDirector
  • NIR SASSIExecutive Officer
  • WALT A LINSCOTTExecutive Officer
Offering amount
$30M
Amount sold
$30M
Sales commissions
$2.1M
Placement agents
H.C. Wainwright & Co., LLC
First sale
Jul 2021
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Indaptus Therapeutics (INDP) sells 20M shares in $12M Regulation S private placementstocktitan.net · Jun 2026Indaptus posts Q1 2026 loss, cash down to $1.5M | INDP 8-K Filingstocktitan.net · May 2026Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazarbarchart.com · Dec 2025Indaptus Therapeutics secures new funding and leadership shift - TipRanks.comtipranks.com · Dec 2025Indaptus Therapeutics raises $5.7 million through convertible notes By Investing.cominvesting.com · Jul 2025Indaptus Therapeutics Secures $2.25M Private Placement for R&D Advancement | INDP Stock Newsstocktitan.net · Jan 2025

Frequently asked questions

Who founded Indaptus Therapeutics?
Indaptus Therapeutics was founded by MICHAEL J. NEWMAN in 2021.
How much funding has Indaptus Therapeutics raised?
Indaptus Therapeutics has disclosed $35M raised across 5 rounds.
Where is Indaptus Therapeutics headquartered?
Indaptus Therapeutics is headquartered in New York, US.